Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid Tumors

NCT05382936 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
20
Enrollment
INDUSTRY
Sponsor class

Stopped The study was stopped after careful consideration of the landscape of similar drugs and evolving standard of care.

Conditions

Interventions

Sponsor

Stemline Therapeutics, Inc.